Polyrizon (PLRZ) entered into a development agreement with Clearmind Medicine (CMND). Under this agreement, Polyrizon will develop a proprietary intranasal formulation of MEAI, Clearmind’s proprietary, next-generation, non-hallucinogenic neuroplastogen drug candidate, intended for use in the treatment of addiction-related and other central-nervous-system conditions.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- Psychedelic: Analyst initiates Definium, Helus with Buy ratings
- Clearmind Medicine welcomes inclusion of MEAI in bipartisan legislation
- Psychedelic: Clearmind completes second cohort treatment for CMND-100 trial
- Clearmind announces completion of treatment for second cohort in CMND-100 trial
- Clearmind Medicine regains compliance with Nasdaq minimum bid price rule